Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,335,968
  • Shares Outstanding, K 221,019
  • Annual Sales, $ 6,070 M
  • Annual Income, $ 603,400 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.25
  • Price/Sales 6.53
  • Price/Cash Flow 8.00
  • Price/Book 3.24
  • Price/Earnings ttm 15.07
  • Earnings Per Share ttm 11.91
  • Most Recent Earnings $3.52 on 04/30/21
  • Next Earnings Date 07/29/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 3.22
  • Number of Estimates 4
  • High Estimate 3.63
  • Low Estimate 2.89
  • Prior Year 2.87
  • Growth Rate Est. (year over year) +12.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
178.51 +2.24%
on 07/19/21
187.45 -2.64%
on 07/14/21
+1.81 (+1.00%)
since 06/18/21
3-Month
164.83 +10.72%
on 04/29/21
187.45 -2.64%
on 07/14/21
+15.96 (+9.58%)
since 04/20/21
52-Week
99.91 +82.66%
on 08/21/20
187.45 -2.64%
on 07/14/21
+72.96 (+66.61%)
since 07/20/20

Most Recent Stories

More News
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS ® (ravulizumab-cwvz) in adults with generalized...

ALXN : 182.50 (+1.70%)
Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Honeywell International Inc. (Nasdaq: HON), will become a component of the NASDAQ-100 Index ® (Nasdaq: NDX), the...

HON : 226.11 (-0.25%)
ALXN : 182.50 (+1.70%)
NDAQ : 80.58 (+0.62%)
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy,...

ALXN : 182.50 (+1.70%)
FBIO : 1.5800 (+0.64%)
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of ULTOMIRIS ® (ravulizumab-cwvz) to include children (one month...

ALXN : 182.50 (+1.70%)
Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, have been accepted for e-poster...

ALXN : 182.50 (+1.70%)
FBIO : 1.5800 (+0.64%)
Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts have been accepted for presentation at the 26 th annual European Hematology Association (EHA) 2021 virtual Congress, taking...

ALXN : 182.50 (+1.70%)
Alexion Shareholders Approve Acquisition by AstraZeneca

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting...

ALXN : 182.50 (+1.70%)
Alexion Reports First Quarter 2021 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021. Total revenues in the first quarter were $1,636.5 million, a 13 percent increase compared to...

ALXN : 182.50 (+1.70%)
UPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on April...

ALXN : 182.50 (+1.70%)
Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on May 3,...

ALXN : 182.50 (+1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

3rd Resistance Point 185.94
2nd Resistance Point 184.31
1st Resistance Point 183.40
Last Price 182.50
1st Support Level 180.86
2nd Support Level 179.23
3rd Support Level 178.32

See More

52-Week High 187.45
Last Price 182.50
Fibonacci 61.8% 154.01
Fibonacci 50% 143.68
Fibonacci 38.2% 133.35
52-Week Low 99.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar